%PDF-1.4
%
34 0 obj
<>
endobj
31 0 obj
<>
endobj
93 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-02-28T18:56:24Z
2024-03-29T04:26-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T04:26-07:00
application/pdf
Heather
2005-13.may
uuid:f775be1b-1dd1-11b2-0a00-100927bd7200
uuid:f775be1e-1dd1-11b2-0a00-880000000000
endstream
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
35 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 10 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
103 0 obj
[107 0 R]
endobj
104 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.06821 Tw 10 0 0 10 65.468 735.6616 Tm
(In standard care, simple patient questionnaires are more)Tj
0.0199 Tc 0.4964 Tw -1.2 -1.2 Td
(than adequate and provide permanent medical and)Tj
-0.00011 Tc -0.0094 Tw 0 -1.2 TD
(medicolegal documentation of patient status at a given time.)Tj
0.1523 Tw T*
(If such a questionnaire is not included in a visit, an irre-)Tj
0.0103 Tw T*
(placeable opportunity is lost for the patient and the rheuma-)Tj
-0.0239 Tw T*
(tologist. Even if small amounts of incremental data might be)Tj
0.0175 Tw T*
[(missed in use of pragmatic of)17.7 (fice questionnaires rather than)]TJ
0.1084 Tw T*
(extensive research questionnaires, we answer our question)Tj
0.0282 Tw T*
(in the title by suggesting that it is better to have 80% of the)Tj
0.041 Tw T*
(information in 100% of patients than 100% of the informa-)Tj
0.05009 Tw T*
(tion in 5% of the patients. Simple clinical patient question-)Tj
0.02499 Tw T*
(naires save time and make us better physicians.)Tj
/T1_1 1 Tf
9.3714 -2.4 Td
(THEODORE PINCUS,)Tj
/T1_0 1 Tf
0 Tw 6 0 0 6 250.1799 579.6616 Tm
(MD, )Tj
0.02499 Tw 8 0 0 8 147.1823 569.6616 Tm
[(Division of Rheumatology and Immunology)64.8 (,)]TJ
0 -1.25 TD
[(V)110.8 (anderbilt University School of Medicine,)]TJ
0 Tc T*
(203 Oxford House, Box 5,)Tj
-0.00011 Tc 0.00729 Tw T*
[(Nashville, T)69.9 (ennessee )-17.7 (37232-4500;)]TJ
/T1_1 1 Tf
10 0 0 10 147.1823 527.6616 Tm
(FREDERICK WOLFE,)Tj
/T1_0 1 Tf
0 Tw 6 0 0 6 252.2233 527.6616 Tm
(MD,)Tj
0.02499 Tw 8 0 0 8 147.1823 517.6616 Tm
(National Data Bank for Rheumatic Diseases,)Tj
T*
[(W)39.8 (ichita, Kansas, USA.)]TJ
/T1_2 1 Tf
-11.7143 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. Pincus, E-mail: t.pincus@vanderbilt.edu)]TJ
/T1_1 1 Tf
0 Tw 10 0 0 10 53.468 463.6616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 60.468 453.6616 Tm
[(1.)-875.1 (Strand )17.7 (V)128.9 (,)-0.1 ( )17.7 (T)35 (ugwell P)110.7 (, Bombardier C, et al. Function and health-)]TJ
1.675 -1.25 Td
(related quality of life: Results from a randomized controlled trial of)Tj
T*
(leflunomide versus methotrexate or placebo in patients with active)Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1999;42:1870-8.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (T)35 (ugwell P)110.7 (,)-0.1 ( )17.7 (W)79.9 (ells G, Strand )17.7 (V)128.9 (, et al. Clinical improvement as)]TJ
1.675 -1.25 Td
(reflected in measures of function and health-related quality of life)Tj
T*
(following treatment with leflunomide compared with methotrexate)Tj
T*
(in patients with rheumatoid arthritis: Sensitivity and relative)Tj
T*
[(ef)17.7 (ficiency to detect a treatment ef)17.7 (fect in a twelve-month, placebo-)]TJ
T*
[(controlled trial. Leflunomide Rheumatoid )54.8 (Arthritis Investigators)]TJ
T*
[(Group. )54.8 (Arthritis Rheum 2000;43:506-14.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Cohen S, Cannon GW)91.7 (, Schif)17.7 (f M, et al. )17.7 (T)69.9 (wo-year)39.7 (, blinded,)]TJ
1.675 -1.25 Td
(randomized, controlled trial of treatment of active rheumatoid)Tj
T*
(arthritis with leflunomide compared with methotrexate. Utilization)Tj
T*
[(of leflunomide in the )17.7 (T)35 (reatment of Rheumatoid )54.8 (Arthritis )17.7 (T)35 (rial)]TJ
T*
[(Investigators Group. )54.8 (Arthritis Rheum 2001;44:1984-92.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Strand )17.7 (V)128.9 (, Cohen S, Crawford B, Smolen JS, Scott DL. Patient-)]TJ
1.675 -1.25 Td
(reported outcomes better discriminate active treatment from)Tj
T*
(placebo in randomized controlled trials in rheumatoid arthritis.)Tj
T*
(Rheumatology Oxford 2004;43:640-7.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Strand )17.7 (V)128.9 (, Cohen S, Schif)17.7 (f M, et al. )17.7 (T)35 (reatment of active rheumatoid)]TJ
1.675 -1.25 Td
(arthritis with leflunomide compared with placebo and methotrexate.)Tj
T*
(Arch Intern Med 1999;159:2542-50.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Smolen JS, Kalden JR, Scott DL, et al. Ef)17.7 (ficacy and safety of)]TJ
1.675 -1.25 Td
(leflunomide compared with placebo and sulphasalazine in active)Tj
T*
[(rheumatoid arthritis: )54.8 (A)-220.1 (double-blind, randomised, multicentre trial.)]TJ
T*
(Lancet 1999;353:259-66.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Emery P)110.7 (, Breedveld FC, Lemmel EM, et al. )54.8 (A)-220.1 (comparison of the)]TJ
1.675 -1.25 Td
[(ef)17.7 (ficacy and safety of leflunomide and methotrexate for the)]TJ
T*
(treatment of rheumatoid arthritis. Rheumatology Oxford)Tj
0 Tc 0 Tw T*
(2000;39:655-65.)Tj
-0.00011 Tc 0.02499 Tw 31.325 72.921 Td
[(8.)-875.1 (Pincus )17.7 (T)74 (, Strand )17.7 (V)128.9 (, Koch G, et al. )54.8 (An index of the three core data)]TJ
1.675 -1.25 Td
[(set patient questionnaire measures distinguishes ef)17.7 (ficacy of active)]TJ
T*
[(treatment from that of placebo as ef)17.7 (fectively as the )54.8 (American)]TJ
T*
(College of Rheumatology 20% response criteria or the disease)Tj
T*
[(activity score in a rheumatoid arthritis clinical trial. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2003;48:625-30.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Pincus )17.7 (T)74 (,)-0.1 ( )54.8 (Amara I, Koch GG. Continuous indices of core data set)]TJ
1.675 -1.25 Td
(measures in rheumatoid arthritis clinical trials: lower responses to)Tj
T*
[(placebo than seen with categorical )54.8 (American College of)]TJ
T*
[(Rheumatology 20% responses \(ACR 20\). )54.8 (Arthritis Rheum 2005; )]TJ
T*
(\(In press\).)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Strand )17.7 (V)128.9 (, Scott DL, Emery P)110.7 (, et al. Physical function and health)]TJ
2.175 -1.25 Td
[(related quality of life: )54.8 (Analysis of 2-year data from randomized)]TJ
T*
(controlled studies of leflunomide, sulfasalazine, or methotrexate in)Tj
T*
(patients with active rheumatoid arthritis. J Rheumatol 2005;)Tj
0 Tc 0 Tw T*
(32:590-601.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Buchbinder R, Bombardier C, )36.8 (Y)99.8 (eung M, )17.7 (T)35 (ugwell P)110.7 (.)-0.1 ( )17.7 (Which outcome)]TJ
2.1381 -1.25 Td
(measures should be used in rheumatoid arthritis clinical trials?:)Tj
T*
[(clinical and quality-of-life measures\325)-201.1 (responsiveness to treatment in)]TJ
T*
[(a randomized controlled trial. )54.8 (Arthritis Rheum 1995;38:1568-80.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (W)79.9 (are JE Jr)54.8 (. SF-36 health survey manual and interpretation guide.)]TJ
2.175 -1.25 Td
(Lincoln, RI: QualityMetric, Inc.; 2000.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Fries JF)79.7 (, Spitz P)110.7 (, Kraines RG, Holman HR. Measurement of patient)]TJ
2.175 -1.25 Td
[(outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Pincus )17.7 (T)74 (, Summey JA, Soraci SA)-220.2 (Jr)39.7 (, )17.7 (W)79.9 (allston KA, Hummon NP)110.7 (.)]TJ
2.175 -1.25 Td
(Assessment of patient satisfaction in activities of daily living using)Tj
T*
[(a modified Stanford Health )54.8 (Assessment Questionnaire. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1983;26:1346-53.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Pincus )17.7 (T)74 (, Callahan LF)79.7 (, Sale )17.7 (WG, Brooks )54.8 (AL, Payne LE, )17.7 (V)110.8 (aughn)]TJ
2.175 -1.25 Td
[(WK. Severe functional declines, work disability)64.8 (, and increased)]TJ
T*
(mortality in seventy-five rheumatoid arthritis patients studied over)Tj
T*
[(nine years. )54.8 (Arthritis Rheum 1984;27:864-72.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Pincus )17.7 (T)74 (,)-0.1 ( Sokka )17.7 (T)74 (. Quantitative measures for assessing rheumatoid)]TJ
2.175 -1.25 Td
(arthritis in clinical trials and clinical care. Best Pract Res Clin)Tj
T*
(Rheumatol 2003;17:753-81.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (W)79.9 (olfe F)79.7 (,)-0.1 ( Michaud K, Choi HK, )17.7 (W)39.8 (illiams R. )54.8 (Annual and lifetime)]TJ
2.175 -1.25 Td
(productivity costs and income losses in persons with rheumatoid)Tj
T*
[(arthritis [abstract]. )54.8 (Arthritis Rheum 2003;48 Suppl:S243.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Pincus )17.7 (T)74 (, Swearingen C, )17.7 (W)79.9 (olfe F)79.7 (.)-0.1 ( )17.7 (T)69.9 (oward a Multidimensional)]TJ
2.175 -1.25 Td
[(Health )54.8 (Assessment Questionnaire \(MDHAQ\): )54.8 (Assessment of)]TJ
T*
(advanced activities of daily living and psychological status in the)Tj
T*
[(patient friendly Health )54.8 (Assessment Questionnaire format. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42:2220-30.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (W)79.9 (olfe F)79.7 (, Michaud K, Pincus )17.7 (T)74 (. Development and validation of the)]TJ
2.175 -1.25 Td
[(Health )54.8 (Assessment Questionnaire II: a revised version of the Health)]TJ
T*
[(Assessment Questionnaire. )54.8 (Arthritis Rheum 2004;50:3296-305.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (W)79.9 (olfe F)79.7 (, Pincus )17.7 (T)74 (. Listening to the patient: )54.8 (A)-220.1 (practical guide to self-)]TJ
2.175 -1.25 Td
[(report questionnaires in clinical care. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1999;42:1797-808.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Pincus )17.7 (T)74 (, Koch G, Lei H. Patient preference for placebo,)]TJ
2.175 -1.25 Td
[(acetaminophen or celecoxib ef)17.7 (ficacy studies \(P)91.7 (ACES\): two)]TJ
T*
(randomized placebo-controlled cross-over clinical trials in patients)Tj
T*
[(with osteoarthritis of the knee or hip. )54.8 (Ann Rheum Dis 2004;)]TJ
0 Tc 0 Tw T*
(63:931-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (W)79.9 (olfe F)79.7 (, Michaud K, Pincus )17.7 (T)74 (. Fatigue, rheumatoid arthritis, and)]TJ
2.175 -1.25 Td
(anti-tumor necrosis factor therapy: an investigation in 24,831)Tj
T*
[(patients. J Rheumatol 2004;31:21)36.8 (15-20.)]TJ
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 545.468 56.4344 Tm
(577)Tj
ET
0 0 0 0 k
53.532 70.5 203 -16.545 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.6894 Tm
[(Pincus and W)91.7 (olfe: Editorial)]TJ
ET
0 0 0 0 k
/GS0 gs
104.585 82.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.585 82.25 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
14 0 obj
<>stream
8;Z\6#u\\q%.jK`kjJN#=H]/K8\2OX5Rk%>9cV8UjLRSGQbl43/;Q`$5/7-sq=*G?
ic0EXE25)k<3TQI]R3*s%rB:I%\t8e%1ZGR%@hsU$#B_oenYI&Xg:`@A4^,nd7LU!
iRHV->RRH)k-@n^U6kGc*L9aSQ2NST8R,4Uf(X:Dc'*3s3&6Kua+TU?_COb.9"U02
$>&Y;`&"]:/'!Ig)LfZ7T@a!-<&eOb<#h[o6.+^225Q@>a&Z;JXr4VY72pf;kHR!0
i&-*_7_f*"&H(o$?,bXhWiG_%]f(Jno3Q0JE-b$T>!`^`.jh+e70(8[o[&BZLjO1[
C/[8$(fL+1'4AilI*au'K`7\iThFCO8BIS`^b9('L(5fMf5rV[S6jU?P3)#5^'WW]
']H+33cs`n]rO0)0kSe^r.[Y6X5.tu3?/a9Yf4F]WiiF+eNj^f"_ODA6W2k@,X+.$
Q4(k"dH2jl@*mr`ap]q!eN&?Z[3"naJR4er9:I\c#7r1*=#OQeu&*'N_p.cr_h+6M3?Vj^-uNc&j>?__kjI(M84,
)tgdf?\Rach3KRq_#P4NCdiJBL2%ZbMBt3G=E0o.kfGlPJMU.9@e2nj7A,_UKjN1s
gI[9#EI0YgQ6Z4W^e)t*m=S)JO>t&4Dr4JRbLp'4U=6u6mbLdaq96i8\b@uqJhTc_
Kd[$(a#?08fVK-ST!i+;*erL?*S8Bq[tQYk+QjqYo=+1n/p!rsq7Zmu~>
endstream
endobj
18 0 obj
[/Indexed/DeviceRGB 255 17 0 R]
endobj
17 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
51 0 obj
<>
endobj
7 0 obj
<>
endobj
37 0 obj
<>
endobj
86 0 obj
<>
endobj
98 0 obj
<>
endobj
38 0 obj
<>
endobj
63 0 obj
<>stream
Ht{Tw'3A ʄΌ.T#>@b 1[CWXP*U;9o{??6IDmWORƩϗ
oyFO<p4ZgjE7E
]OE"}|hSuݱI(onRvɄ~>&RmK'(N)T9?.:AmUUdtƜZ)$2Z41u&)U9eB"S~}zuZSvb1b]bl-ab{_-ŰUNX3a
1 c
-3ug0Ij1"$]/r0yɏGLugjײWnnnLX4ЀQT߉WtM\e-V1!1)L!`@0nAKȸ,A"[vTw$6t{UZVwbLzB:G$ <̳j_t{CO:#ĢP$'dB8#3WTtσ
Zwh5&W,<]g5MY,bY;L=d"^@{KN3h+RB 7pJxM/D>Lm^_5b̦=[Y4 grC>9XSq_u^axȖpObG#ٶ_;RD{@J:u6}wu֕tL:R͐OX+}0[-j>S@